Athenex presents interim data from phase 1 anchor study of kur-502 (allogeneic cd19 car-nkt cells) in relapsed or refractory lymphoma and leukemia at the 2022 transplantation & cellular (“tandem”) meetings of astct and cibmtr

Buffalo, n.y., april 25, 2022 (globe newswire) -- athenex, inc., (nasdaq: atnx), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced data from the anchor phase 1 study of kur-502 during an oral presentation by carlos ramos, m.d., professor, center for cell and gene therapy, baylor college of medicine, at the tandem meetings of the american society of transplantation and cellular therapy (astct), and the center for international blood & marrow transplant research (cibmtr), taking place april 23 to 26, in salt lake city, ut.
ATNX Ratings Summary
ATNX Quant Ranking